Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Livzon Pharmaceutical Group ( (HK:1513) ) is now available.
Livzon Pharmaceutical Group Inc. has announced a board meeting scheduled for October 23, 2025, to consider and approve the unaudited quarterly results for the nine months ending September 30, 2025. This meeting is significant for stakeholders as it will provide insights into the company’s financial performance and strategic direction for the upcoming quarters.
The most recent analyst rating on (HK:1513) stock is a Buy with a HK$48.00 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. operates in the pharmaceutical industry, focusing on the development, manufacturing, and distribution of pharmaceutical products. The company is based in Zhuhai, China, and is involved in providing a range of healthcare solutions.
Average Trading Volume: 2,152,537
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$35.98B
For an in-depth examination of 1513 stock, go to TipRanks’ Overview page.